Neurobiology of cancer: Adrenergic signaling and drug repurposing

Pharmacol Ther. 2024 Dec:264:108750. doi: 10.1016/j.pharmthera.2024.108750. Epub 2024 Nov 10.

Abstract

Cancer neuroscience, as an emerging converging discipline, provides us with new perspectives on the interactions between the nervous system and cancer progression. As the sympathetic nervous system, in particular adrenergic signaling, plays an important role in the regulation of tumor activity at every hierarchical level of life, from the tumor cell to the tumor microenvironment, and to the tumor macroenvironment, it is highly desirable to dissect its effects. Considering the far-reaching implications of drug repurposing for antitumor drug development, such a large number of adrenergic receptor antagonists on the market has great potential as one of the means of antitumor therapy, either as primary or adjuvant therapy. Therefore, this review aims to summarize the impact of adrenergic signaling on cancer development and to assess the status and prospects of intervening in adrenergic signaling as a therapeutic tool against tumors.

Keywords: Adrenergic receptor; Beta-blocker; Cancer neuroscience; Chronic stress; Drug repurposing; Tumor macroenvironment; Tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Adrenergic Antagonists / pharmacology
  • Adrenergic Antagonists / therapeutic use
  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Drug Repositioning*
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Receptors, Adrenergic / metabolism
  • Signal Transduction* / drug effects
  • Sympathetic Nervous System / drug effects
  • Tumor Microenvironment / drug effects

Substances

  • Antineoplastic Agents
  • Receptors, Adrenergic
  • Adrenergic Antagonists